Daniel Lang - 20 Jul 2022 Form 4 Insider Report for Athenex, Inc.

Role
Pres Cell Therapy, VP Corp Dev
Signature
/s/Steven Adams, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
20 Jul 2022
Net transactions value
$0
Form type
4
Filing time
21 Jul 2022, 17:28:27 UTC
Previous filing
01 Dec 2021
Next filing
19 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ATNX Common Stock 73,413 20 Jul 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATNX Stock Option (Right to Buy) Award $0 +200,000 $0.000000 200,000 20 Jul 2022 Common Stock 200,000 $0.6655 Direct F6
holding ATNX Stock Option (Right to Buy) 40,000 20 Jul 2022 Common Stock 40,000 $10.25 Direct F2
holding ATNX Stock Option (Right to Buy) 50,000 20 Jul 2022 Common Stock 50,000 $2.77 Direct F3
holding ATNX Restricted Stock Units 50,000 20 Jul 2022 Common Stock 50,000 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 30,000 shares subject to a restricted stock award vesting in four equal annual installments beginning on August 26, 2020.
F2 This option vests in four equal annual installments beginning on August 27, 2021.
F3 This option vests in four equal annual installments beginning on September 16, 2022.
F4 Each restricted stock unit represents a contingent right to receive one share of stock.
F5 The restricted stock units vest in four equal annual installments beginning on September 16, 2022.
F6 This option vests in four equal annual installments beginning on July 20, 2023.